Both experimental and preclinical studies have demonstrated that persistent activation of PI3K/Akt and/or Ras/Erk pathways is associated with EGFR-TKI resistance in NSCLC, in which they play pivotal roles in TKI sensitivity [66]. Here, AKT1 is linked to non-small cell lung carcinoma.